Skip to main content
. 1998 Apr 20;187(8):1261–1271. doi: 10.1084/jem.187.8.1261

Figure 4.

Figure 4

Effects of Bcl-2 on PTPC. Hexokinase-enriched fractions (Fig. 1 A, 3) were incorporated into liposomes by dialysis in the presence or absence of recombinant Bcl-2, Bcl-2 (Gly145Ala), Bcl-2Δα5/6, or Bcl-XL, followed by functional analysis. (A) Representative fluorescence profiles of control PTPC and Bcl-2 PTPC liposomes treated with buffer only (control), SDS, or Atr, followed by incubation with DiOC6(3). Note the absence of Atr effects in Bcl-2 PTPC liposomes. (B) Incorporation of native and mutant Bcl-2 proteins into liposomes. Proteins were extracted from PTPC liposomes prepared in the presence or absence of the indicated Bcl-2 mutant, followed by immunochemical quantitation of Bcl-2 with a monoclonal antibody that recognizes an epitope (residues 20-34) not affected by the mutations. (C) Functional impact of Bcl-2 and Bcl-XL. The different PTPC liposome preparations were treated with Atr (25 μM), CaCl2 (25 μM), diamide (500 μM), or ter-butylhydroperoxide (tBHP, 500 μM) to determine the DiOC6(3) release. Results are representative for three to five independent experiments. 100% DiOC6(3) release was defined as the SDS-induced reduction of DiOC6(3) fluorescence observed in PTPC liposomes generated in the absence of Bcl-2 or Bcl-XL.